Pfizer’s Allergan Play Could Deliver Tax-Inversion, But No OTCs
This article was originally published in The Tan Sheet
Executive Summary
Pfizer and Allergan are in friendly merger talks, but the US likely will not be amiable about another pharma giant re-incorporating abroad. Should a deal happen, Allergan’s generic OTC business would not be included, says Teva, awaiting antitrust clearance to close its acquisition of the Irish firm’s generic operations.